0%

est. 2Y upside i

HealthcareSeries A

Power Life Science believes that every patient deserves the chance to participate in a life-changing clinical trial. Is backed by some of the best healthcare investors and operators with a range of experience across clinical research and biopharmaceuticals. We are a small team - each of us with our own personal story and motivation to make a difference in the lives of patients.

Rank

#2135

Sector

HealthTech

Est. Liquidity

~5Y

Data Quality

Data: Low

Due to incomplete financial data, equity upside cannot be reliably estimated.

Last updated: July 19, 2026

Bull (20%)0%

Cannot compute due to missing valuation and revenue data.

Base (55%)0%

Cannot compute due to missing valuation and revenue data.

Bear (25%)0%

Cannot compute due to missing valuation and revenue data.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

0%

Total funding of $19M with unknown valuation implies preferred stack may represent a significant portion of the cap table.

Dilution Risk

moderate

Series A closed Dec 2023; likely to raise a Series B within 2 years, causing additional dilution.

Secondary Liquidity

none

No secondary market activity detected; liquidity would require an IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Power's data — designed to show you've done your homework.

  • 1

    “What is the current annual recurring revenue and growth rate?”

  • 2

    “How does the business model work—what are the unit economics per patient/trial?”

  • 3

    “What is the current valuation and implied ownership dilution for new hires?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.